Unlocking the potential of retinoic acid in anticancer therapy

All-trans-retinoic acid (ATRA) is a physiologically active metabolite of vitamin A. Its antitumour activities have been extensively studied in a variety of model systems and clinical trials; however, to date the only malignancy responsive to ATRA treatment is acute promyelocytic leukaemia (APL) where it induces complete remission in the majority of cases when administered in combination with light chemotherapy and/or arsenic trioxide. After decades of studies, the efficacy of ATRA to treat other acute myeloid leukaemia (AML) subtypes and solid tumours remains poor. Recent studies directed to improve ATRA responsiveness in non-APL AML seem to indicate that the lack of effective ATRA response in these tumours may be primarily due to aberrant epigenetics, which negatively affect ATRA-regulated gene expression and its antileukaemic activity. Epigenetic reprogramming could potentially restore therapeutic effects of ATRA in all AML subtypes. This review discusses the current progresses in the understanding how ATRA can be utilised in the therapy of non-APL AML and other cancers.

[1]  M. Huang,et al.  [Treatment of acute promyelocytic leukemia by retinoic acid with or without low dose cytosine arabinoside: report of 4 cases]. , 1987, Zhonghua nei ke za zhi.

[2]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[3]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[4]  C. Huff,et al.  Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia , 2005, British journal of haematology.

[5]  S. Collins,et al.  Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Ponder,et al.  Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers , 2011, International journal of cancer.

[7]  A. Zelent,et al.  Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. , 2005, Blood.

[8]  L. Altucci,et al.  Retinoids: potential in cancer prevention and therapy , 2004, Expert Reviews in Molecular Medicine.

[9]  H. Stunnenberg,et al.  Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. , 2014, Cancer Research.

[10]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[11]  Martin Dugas,et al.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia , 2012, Nature Medicine.

[12]  M. Panigada,et al.  Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells , 2005, The EMBO journal.

[13]  Lucia Altucci,et al.  The promise of retinoids to fight against cancer , 2001, Nature Reviews Cancer.

[14]  S. Fröhling,et al.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B , 2009, Haematologica.

[15]  J. Licht,et al.  Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. , 2003, Best practice & research. Clinical haematology.

[16]  R. Losson,et al.  Trim24 (Tif1 alpha): an essential 'brake' for retinoic acid-induced transcription to prevent liver cancer. , 2008, Cell cycle.

[17]  Y. Saunthararajah,et al.  Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. , 1999, Cancer research.

[18]  P. Hughes,et al.  Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia , 2012, Leukemia research and treatment.

[19]  P. Chambon,et al.  Phosphorylation by p38MAPK and recruitment of SUG‐1 are required for RA‐induced RARγ degradation and transactivation , 2002, The EMBO journal.

[20]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[21]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[23]  L. Pagano,et al.  All-trans Retinoic Acid in Association with Low Dose Cytosine Arabinoside in the Treatment of Acute Myeoid Leukemia in Elderly Patients , 2007, American journal of therapeutics.

[24]  Arthur,et al.  Inhibition of the LSD 1 ( KDM 1 A ) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia , 2013 .

[25]  R. Losson,et al.  Trim24 (Tif1α): An essential ‘brake’ for retinoic acid-induced transcription to prevent liver cancer , 2008 .

[26]  A. Burnett,et al.  Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. , 2006, Blood.

[27]  S. Minucci,et al.  Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL , 2012, Leukemia.

[28]  M. Boix-Chornet,et al.  DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. , 2008, Blood.

[29]  H. Kantarjian,et al.  Epigenetics of acute lymphocytic leukemia. , 2009, Seminars in hematology.

[30]  M. Tribalto,et al.  All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia. , 1995, Leukemia.

[31]  Chris Cain.  AML takes LSD1 , 2012 .

[32]  R. Jagus,et al.  Thioredoxin Reductase Mediates Cell Death Effects of the Combination of Beta Interferon and Retinoic Acid , 1998, Molecular and Cellular Biology.

[33]  P. Pandolfi,et al.  Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. , 2001, The Journal of clinical investigation.

[34]  C. Rochette-Egly,et al.  Vitamin A and retinoid signaling: genomic and nongenomic effects , 2013, Journal of Lipid Research.

[35]  E. Estey,et al.  Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. , 2001, The Journal of clinical investigation.

[36]  S. Gery,et al.  Inhibition of mammalian target of rapamycin signaling potentiates the effects of all‐trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells , 2009, International journal of cancer.

[37]  P. Chambon,et al.  Multiplicity generates diversity in the retinoic acid signalling pathways. , 1992, Trends in biochemical sciences.

[38]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.